Stay updated with breaking news from Ariad Pharm. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
IAM is a unique and timely intelligence service that treats IP as a business asset and tool rather than simply as a legal right, informing boardrooms worldwide.
The Supreme Court's decision to grant certiorari in Amgen v. Sanofi is the first time in almost a hundred years that the Court has deigned to consider sufficiency of disclosure...
IAM is a unique and timely intelligence service that treats IP as a business asset and tool rather than simply as a legal right, informing boardrooms worldwide.
Since the beginning, the United States has been the global leader in developing biotechnology. This dominance has been attributed, in…
Explosive growth of antibody technology and therapeutics over the past three decades has driven development of antibody-centric patent case law across several fronts.